Uger
Marc Uger, San Mateo, CA US
Patent application number | Description | Published |
---|---|---|
20110039725 | DYNAMIC ARRAY ASSAY METHODS - High throughput methods are used that combine the features of using a matrix-type microfluidic device, labeled nucleic acid probes, and homogenous assays to detect and/or quantify nucleic acid analytes. The high throughput methods are capable of detecting nucleic acid analyes with high PCR and probe specificity, producing a low fluorescence background and therefore, a high signal to noise ratio. Additionally, the high throughput methods are capable of detecting low copy number nucleic acid analyte per cell. | 02-17-2011 |
Robert Uger, Ontario CA
Patent application number | Description | Published |
---|---|---|
20130102532 | HB-EGF Composition and Use Thereof to Treat a Condition Associated With Enhanced Urothelium Permeability - HB-EGF is exploited to treat conditions associated with enhanced urothelium permeability, including interstitial cystitis. | 04-25-2013 |
Robert Adam Uger, Richmond Hill CA
Patent application number | Description | Published |
---|---|---|
20150329616 | Treatment of CD47+ Disease Cells with SIRP Alpha-FC Fusions - CD47+ disease cells, such as CD47+ cancer cells, are treated with an agent that blocks signalling via the SIRPα/CD47 axis. The agent is a human SIRPα fusion protein that displays negligible CD47 agonism and negligible red blood cell binding. The fusion protein comprises an IgV domain from variant 2 of human SIRPα, and an Fc having effector function. The IgV domain binds human CD47 with an affinity that is at least five fold greater than the affinity of the entire extracellular region of human SIRPα. The fusion protein is at least 5 fold more potent than a counterpart lacking effector function. | 11-19-2015 |